Didu S T Kariyawasam1,2, Jacqueline S Russell3, Veronica Wiley4,5, Ian E Alexander6,7, Michelle A Farrar8,9. 1. Department of Neurology, Sydney Children's Hospital, Randwick, Sydney, NSW, Australia. didu.kariyawasam@health.nsw.gov.au. 2. School of Women's and Children's Health, University of New South Wales Medicine, University of New South Wales, Sydney, NSW, Australia. didu.kariyawasam@health.nsw.gov.au. 3. Department of Genetics, Sydney Children's Hospital, Randwick, Sydney, NSW, Australia. 4. NSW Newborn Screening Programme, Children's Hospital Westmead, Westmead, NSW, Australia. 5. Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. 6. Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney and Sydney Children's Hospital Network, Sydney, NSW, Australia. 7. Discipline of Child and Adolescent Health, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. 8. Department of Neurology, Sydney Children's Hospital, Randwick, Sydney, NSW, Australia. 9. School of Women's and Children's Health, University of New South Wales Medicine, University of New South Wales, Sydney, NSW, Australia.
Abstract
PURPOSE: To evaluate the implementation of the first statewide newborn screening (NBS) program for spinal muscular atrophy (SMA) in Australia. Processes that hinder and support clinical development, translation, and sustainability of the first primary genetic screening program in Australia are appraised. METHODS: The study prospectively describes the course (timelines, health processes, and preliminary clinical outcomes) for SMA screen-positive newborns from 1 August 2018 to 31 July 2019 in New South Wales and Australian Capital Territory, Australia. RESULTS: In the first year of the program, 103,903 newborns were screened. Ten newborns screened positive for SMA. Genetic confirmation of SMA occurred in 9/10 (90%) of infants. Clinical signs of SMA evolved in 4/9 (44%) within 4 weeks of life, heralded by hypotonia and weakness initially recognized in the neck. Median time to implementing a care plan (including commencement of disease-modifying therapies) was 26.5 days (16-37 days) from birth. CONCLUSION: NBS is essential for early and equitable identification of patients with SMA. Expedient diagnosis and management are vital, as disease latency appears brief in some cases. NBS shows significant clinical utility to support early parental decision making, improve access to specialist neuromuscular expertise, and facilitate initiation of personalized therapeutic strategies.
PURPOSE: To evaluate the implementation of the first statewide newborn screening (NBS) program for spinal muscular atrophy (SMA) in Australia. Processes that hinder and support clinical development, translation, and sustainability of the first primary genetic screening program in Australia are appraised. METHODS: The study prospectively describes the course (timelines, health processes, and preliminary clinical outcomes) for SMA screen-positive newborns from 1 August 2018 to 31 July 2019 in New South Wales and Australian Capital Territory, Australia. RESULTS: In the first year of the program, 103,903 newborns were screened. Ten newborns screened positive for SMA. Genetic confirmation of SMA occurred in 9/10 (90%) of infants. Clinical signs of SMA evolved in 4/9 (44%) within 4 weeks of life, heralded by hypotonia and weakness initially recognized in the neck. Median time to implementing a care plan (including commencement of disease-modifying therapies) was 26.5 days (16-37 days) from birth. CONCLUSION: NBS is essential for early and equitable identification of patients with SMA. Expedient diagnosis and management are vital, as disease latency appears brief in some cases. NBS shows significant clinical utility to support early parental decision making, improve access to specialist neuromuscular expertise, and facilitate initiation of personalized therapeutic strategies.
Authors: Lingling Kong; David O Valdivia; Christian M Simon; Cera W Hassinan; Nicolas Delestrée; Daniel M Ramos; Jae Hong Park; Celeste M Pilato; Xixi Xu; Melissa Crowder; Chloe C Grzyb; Zachary A King; Marco Petrillo; Kathryn J Swoboda; Crystal Davis; Cathleen M Lutz; Alexander H Stephan; Xin Zhao; Marla Weetall; Nikolai A Naryshkin; Thomas O Crawford; George Z Mentis; Charlotte J Sumner Journal: Sci Transl Med Date: 2021-01-27 Impact factor: 17.956
Authors: Eugenio Mercuri; Charlotte J Sumner; Francesco Muntoni; Basil T Darras; Richard S Finkel Journal: Nat Rev Dis Primers Date: 2022-08-04 Impact factor: 65.038
Authors: Kevin A Strauss; Michelle A Farrar; Francesco Muntoni; Kayoko Saito; Jerry R Mendell; Laurent Servais; Hugh J McMillan; Richard S Finkel; Kathryn J Swoboda; Jennifer M Kwon; Craig M Zaidman; Claudia A Chiriboga; Susan T Iannaccone; Jena M Krueger; Julie A Parsons; Perry B Shieh; Sarah Kavanagh; Sitra Tauscher-Wisniewski; Bryan E McGill; Thomas A Macek Journal: Nat Med Date: 2022-06-17 Impact factor: 87.241
Authors: Kevin A Strauss; Michelle A Farrar; Francesco Muntoni; Kayoko Saito; Jerry R Mendell; Laurent Servais; Hugh J McMillan; Richard S Finkel; Kathryn J Swoboda; Jennifer M Kwon; Craig M Zaidman; Claudia A Chiriboga; Susan T Iannaccone; Jena M Krueger; Julie A Parsons; Perry B Shieh; Sarah Kavanagh; Melissa Wigderson; Sitra Tauscher-Wisniewski; Bryan E McGill; Thomas A Macek Journal: Nat Med Date: 2022-06-17 Impact factor: 87.241
Authors: Arlene M D'Silva; Didu S T Kariyawasam; Stephanie Best; Veronica Wiley; Michelle A Farrar Journal: Dev Med Child Neurol Date: 2021-11-28 Impact factor: 4.864